Monitor for any future conversion of this 13G to a 13D, which would signal a shift from passive to activist intent. For now, the filing is a routine passive stake update with no immediate trading implications.
ALNY drugs
ALNY drug pipeline →- ● brezosiran 3/10 Phase 1b
- ● GIVLAARI 3/10 Approved (FDA approval 2019-11-20)
- ● ONPATTRO 3/10 Approved (marketed); Phase 3 (APOLLO-B) completed
- ● OXLUMO 3/10 Approved
- ● ALN-6222 2/10 unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
- 2 more · All ALNY drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $165.04entry
- T+1 · 21h ago −3.22%α −1.31% · $159.73
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Capital World Investors filed an amended Schedule 13G disclosing a 10.4% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, up from a prior filing. This is a routine update for a large passive holder and does not signal any change in investment intent or control.
Key Financial Metrics
Key Facts
- Capital World Investors reported beneficial ownership of 13,934,539 shares of Alnylam common stock, representing 10.4% of shares outstanding as of September 30, 2026.
- The filing is an amendment to Schedule 13G, certifying passive investment intent under Rule 13d-1(b).
- The stake increased from the prior filing (May 2026), which disclosed a lower percentage but no exact prior figure is stated in this document.
- The filing was made on November 13, 2026, with a signature date of November 11, 2026.
Financial Impact
Capital World Investors holds 13,934,539 shares, valued at approximately $1.5B based on the $21.4B market cap and 133,875,000 shares outstanding.
Risk Factors
- No material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001422849-26-000177 |
| Document: 0001422849-26-000177-index.html | 0001422849-26-000177 |
| Document: 0001422849-26-000177.txt | 0001422849-26-000177 |
Track record
15 reports on ALNY
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers